NEOPHARMED GENTILI acquired by ARDIAN

Eurazeo Capital completed the acquisition of 100% of the share capital of D.O.R.C. from its previous owners. The transaction positions Eurazeo as the majority shareholder of a rapidly growing MedTech player in the dynamic ophthalmic surgery market. The strategic plan focuses on capitalizing on D.O.R.C.'s highly regarded brand and innovative technology to drive further international growth, with a specific priority on capturing market share in the US. Eurazeo also intends to support the company's shift towards a higher mix of recurring revenue through its proprietary consumables and surgical packs.

The global life sciences leader has finalized the acquisition of 100% of the share capital of the target from a prominent European private equity firm. This strategic transaction represents a definitive move to incorporate advanced digital capabilities into the group’s specialized animal health division, targeting the high-growth segment of animal intelligence and monitoring. The strategic rationale for the move centers on the acquirer's objective to provide integrated, data-driven health management solutions that complement its existing portfolio of vaccines and medicines. By incorporating this technical specialist, the organization reinforces its ability to offer comprehensive traceability and real-time health insights for livestock and companion animals. The partnership is designed to leverage the acquirer’s global reach and research infrastructure to accelerate the development of next-generation monitoring technologies. This integration facilitates the creation of a premier digital platform in the animal health market, providing the strategic depth required to address the rising demand for food security and enhanced pet longevity.

The acquisition of Nemera by Astorg Partners is a strategic move to capitalize on the company's strong market position, predictable revenue streams, and significant growth potential. The deal is driven by the attractiveness of Nemera's business model, which is characterized by long-term contracts, high recurrence rates, and a strong track record of EBITDA growth. Astorg Partners' investment in Nemera is expected to support the company's continued growth and expansion, with a focus on driving innovation, improving operational efficiency, and enhancing customer satisfaction. The transaction is also expected to provide a strong return on investment for Astorg Partners, given Nemera's solid financial performance and growth prospects. The deal process was highly competitive, with several strategic and financial buyers participating in the auction, and Astorg Partners' offer was distinguished by its attractive financial terms and compelling growth strategy.

Bridgepoint has acquired a majority stake in HTL, the specialized producer of hyaluronic acid, in a secondary LBO transaction from Naxicap Partners. This operation follows a period of rapid development under the previous sponsor, which had orchestrated a management buy-in (MBI) only eighteen months prior. In this new capital structure, Naxicap Partners retains a significant minority interest, signaling continued confidence in the company's growth trajectory and industrial potential. The rationale for the transaction is rooted in HTL,s exceptional profitability and its unique position in a high-barrier-to-entry niche of the biotechnology sector. With Bridgepoint,s support, HTL aims to accelerate its international transformation, moving beyond its historical European stronghold to capture market share in North America and Asia.

Ardian acquired a majority stake in Inula from Vendis Capital and founder Dominique Baudoux. The founder and Vendis Capital retained reinvestment options, while the CEO and the management team reinvested significantly to increase their equity stake. The acquisition aimed to leverage Ardian's global footprint to accelerate Inula's expansion in the US, Italy, and Germany, and to pursue buy-and-build opportunities in the fragmented aromatherapy market.

The acquisition of Acteon by Dentressangle represents a major turning point in the medtech’s trajectory, moving toward an aggressive buy-and-build strategy. The strategic rationale for this transaction centers on an "industrial-consolidation" play, merging the group’s industry-leading technical operational depth in ultrasonic surgery with the sponsor’s extensive expertise in executing international build-up operations. This structural alignment provides the organization with the institutional capital and strategic guidance required to address the increasing demand for integrated dental technology suites. This operation allows the group to execute a definitive structural expansion of its product portfolio by identifying specialized family-owned companies to complement its imaging and hardware lines. By incorporating the sponsor’s strategic discipline, the group is now positioned to leverage its recognized leadership in the United States, China, and Japan to drive deeper market penetration. The maneuver optimizes the group’s financial profile, utilizing a robust unitranche facility provided by Capzanine to fund an ambitious roadmap of external growth. Ultimately, the partnership solidifies the group’s standing as a primary enabler of medtech innovation, bridging the gap between sophisticated laboratory-scale imaging science and industrialized clinical manufacturing standards.

Permira, the global private equity firm, acquired a majority stake in Corin Group, a UK-based leader in orthopaedic innovation, from a consortium of investors including DeA Capital, Hunt Capital, and IP (Investimenti e Partecipazioni). Permira's thesis was centered on accelerating Corin's international scale—particularly in the US and Australian markets—and fueling an aggressive buy-and-build strategy to integrate digital health and robotic capabilities into the core implant business. This approach aimed to position Corin as a "Challenger OEM" capable of disrupting larger incumbents through superior product innovation and data-driven patient monitoring.

The integration of Paragon Medical into the NN, Inc. life sciences portfolio represents a definitive shift in the group's overarching corporate strategy. By absorbing Paragon Medical, NN, Inc. significantly enhances its technical proficiencies and diversifies its finished device offerings, moving beyond traditional industrial components into highly regulated healthcare markets. The strategic rationale for the transaction centers on the fusion of Paragon Medical’s niche leadership in orthopedic instrumentation with NN, Inc.’s global manufacturing scale and materials science depth. This operation allows NN, Inc. to build a more balanced business model, mitigating exposure to volatile industrial cycles by capturing non-discretionary demand in the surgical hardware space. The partnership acts as a catalyst for geographic and technical expansion, providing the strategic resources required to scale Paragon Medical's specialized capabilities across an international platform. Ultimately, the merger consolidates a high-performance life sciences division, positioning the organization as a primary enabler of medical device innovation and precision manufacturing on a global scale.

PerkinElmer, Inc. has entered into a definitive agreement to acquire 100% of EUROIMMUN Medical Laboratory Diagnostics. The transaction aims to significantly expand PerkinElmer's reach into the autoimmune and allergy diagnostic markets, while simultaneously strengthening its presence in China and other emerging markets. By combining EUROIMMUN’s expertise in immunology and infectious diseases with PerkinElmer's established leadership in reproductive health and genomic offerings, the merged entity will offer a more robust suite of diagnostic solutions globally. The strategic rationale includes leveraging EUROIMMUN’s high-growth profile (averaging 19% revenue growth over five years) to accelerate PerkinElmer’s overall earnings. Additionally, the acquisition allows PerkinElmer to drive EUROIMMUN’s specialized solutions through its well-established U.S. commercial channels.

CVC and the Canadian company CDPQ are acquiring control of the medical diagnostics specialist Sebia. The company is valued at nearly EUR2 billion, according to multiple sources.